Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy

Kidney International

Volumn 70, Issue 5, 2006, Pages 882-891

  Wang, Y ^a   Zhou, J ^a   Minto, A W ^a   Hack, B K ^a   Alexander, J J ^a   Haas, M ^b   Li, Y C ^a   Heilig, C W ^a   Quigg, R J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Calcium; Diabetes mellitus; Diabetic nephropathy; Extracellular matrix; Vitamin D

Indexed keywords

CALBINDIN; CALCITRIOL; CALCYCLIN; COLLAGEN TYPE 4; FIBRONECTIN; GLUCOSE; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; VITAMIN D3 1ALPHA HYDROXYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENETIC TRANSCRIPTION; GLOMERULUS; KIDNEY TUBULE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CALCITRIOL; CALCIUM; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KIDNEY GLOMERULUS; MICE; MICE, MUTANT STRAINS; PODOCYTES; RECEPTORS, CALCITRIOL; RNA, MESSENGER; UP-REGULATION; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 33747867785     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001624     Document Type: Article

References (69)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
2. Pugliese A, Eisenbarth GS. Type 1 diabetes mellitus of man: genetic susceptibility and resistance. Adv Exp Med Biol 2004; 552: 170-203.
3. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
4. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
5. van Etten V, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D(3): Basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
6. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
7. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209: 142-145.
8. Luong K, Nguyen LT, Nguyen DN. The role of vitamin D in protecting type 1 diabetes mellitus. Diabetes Metab Res Rev 2005; 21: 338-346.
9. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005; 48: 1247-1257.
10. Eggers PW. Medicare's end stage renal disease program. Health Care Financ Rev 2000; 22: 55-60.
11. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003; 112: 1788-1790.
12. US Renal Data System. USRDS 2004 Annual Data Report. National Institutes of Health, NIDDK: Bethesda, MD, 2004.
13. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88: 1001-1036.
14. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
15. Heilig CW, Liu Y, England RL et al. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy801. Diabetes 1997; 46: 1030-1039.
16. Doi T, Striker LJ, Quaife C et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol 1988; 131: 398-403.
17. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
18. Kelly DJ, Gilbert RE, Cox AJ et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-2107.
19. Riser BL, DeNichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
20. Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1383-1395.
21. Breyer MD, Bottinger E, Brosius III FC et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45.
22. McIntosh CHS, Pedeson RA. Noninsulin-dependent animal models of diabetes mellitus. In: McNeill JH (ed). Experimental Models of Diabetes. CRC Press: Boca Raton, FL, 1999, pp 337-398.
23. Chen H, Charlat O, Tartaglia LA et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.
24. Like AA, Lavine RL, Poffenbarger PL, Chick WL. Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria. Am J Pathol 1972; 66: 193-224.
25. Gärtner K. Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (C57Bl/6J db/db and C57Bl/KSJ db/db). Diabetologia 1978; 15: 59-63.
26. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144.
27. Osterby R, Gall MA, Schmitz A et al. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1064-1070.
28. Breyer MD, Bottinger E, Brosius FC et al. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 2005; 12: 128-145.
29. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med 2005; 5: 509-525.
30. Wada J, Makino H, Kanwar YS. Gene expression and identification of gene therapy targets in diabetic nephropathy. Kidney Int 2002; 61: 73-78.
31. Wada J, Zhang H, Tsuchiyama Y et al. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis. Kidney Int 2001; 59: 1363-1373.
32. Susztak K, Bottinger E, Novetsky A et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004; 53: 784-794.
33. Mishra R, Emancipator SN, Miller C et al. Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am J Physiol Renal Physiol 2004; 286: F913-F921.
34. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.
35. Song YH, Ray K, Liebhaber SA, Cooke NE. Vitamin D-binding protein gene transcription is regulated by the relative abundance of hepatocyte nuclear factors 1alpha and 1beta. J Biol Chem 1998; 273: 28408-28418.
36. Kawashima H, Torikai S, Kurokawa K. Localization of 25-hydroxyvitamin D3 1 alpha-hydroxylase and 24-hydroxylase along the rat nephron. Proc Natl Acad Sci USA 1981; 78: 1199-1203.
37. Hendrix I, Anderson PH, Omdahl JL et al. Response of the 5′-flanking region of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene to physiological stimuli using a transgenic mouse model. J Mol Endocrinol 2005; 34: 237-245.
38. Zehnder D, Bland R, Walker EA et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol 1999; 10: 2465-2473.
39. Sunn KL, Cock TA, Crofts LA et al. Novel N-terminal variant of human VDR. Mol Endocrinol 2001; 15: 1599-1609.
40. Ward DT, Yau SK, Mee AP et al. Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 2001; 12: 779-790.
41. Ishida H, Cunningham NS, Henry HL, Norman AW. The number of 1,25-dihydroxyvitamin D3 receptors is decreased in both intestine and kidney of genetically diabetic db/db mice. Endocrinology 1988; 122: 2436-2443.
42. Matsunuma A, Kawane T, Maeda T et al. Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 2004; 145: 1367-1375.
43. Bland R, Zehnder D, Hewison M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase along the nephron: new insights into renal vitamin D metabolism. Curr Opin Nephrol Hypertens 2000; 9: 17-22.
44. 3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 2005; 161: 755-765.
45. Howard GA, Turner RT, Sherrard DJ, Baylink DJ. Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem 1981; 256: 7738-7740.
46. Bikle DD, Nemanic MK, Gee E, Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest 1986; 78: 557-566.
47. Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515.
48. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 2000; 25: 141-148.
49. Lundgren S, Carling T, Hjalm G et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997; 45: 383-392.
50. Arbour NC, Prahl JM, Deluca HF. Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. Mol Endocrinol 1993; 7: 1307-1312.
51. Healy KD, Frahm MA, Deluca HF. 1,25-dihydroxyvitamin D3 up-regulates the renal vitamin D receptor through indirect gene activation and receptor stabilization. Arch Biochem Biophys 2005; 433: 466-473.
52. Esteban LM, Fong C, Amr D et al. Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochem Biophys Res Commun 2005; 334: 9-15.
53. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005; 16: 261-266.
54. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
55. Marshall SM. The podocyte: a major player in the development of diabetic nephropathy? Horm Metab Res 2005; 37(Suppl 1): 9-16.
56. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
57. Dalla VM, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
58. Panichi V, Migliori M, Taccola D et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60: 87-95.
59. Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001; 158: 1733-1741.
60. Li Y, Spataro BC, Yang J et al. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-1510.
61. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
62. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
63. Nagai Y, Yao L, Kobori H et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16: 703-711.
64. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039-F1045.
65. Christakos S, Liu Y. Biological actions and mechanism of action of calbindin in the process of apoptosis. J Steroid Biochem Mol Biol 2004; 89-90: 401-404.
66. Li YC, Bolt MJ, Cao LP, Sitrin MD. Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. Am J Physiol Endocrinol Metab 2001; 281: E558-E564.
67. Zheng W, Xie Y, Li G et al. Critical role of calbindin-D28k in calcium homeostasis revealed by mice lacking both vitamin D receptor and calbindin-D28k. J Biol Chem 2004; 279: 52406-52413.
68. Ren G, Doshi M, Hack BK et al. Isolation and characterization of a novel rat factor H-related protein that is up-regulated in glomeruli under complement attack. J Biol Chem 2002; 277: 48351-48358.
69. Doi T, Hattori M, Agodoa LY et al. Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia. Lab Invest 1990; 63: 204-212.